Dr. Ian Pavord and Dr. Simon Couillard, ATS 2021: The ORACLE Scale for the Prediction of Asthma Attacks
We had the great pleasure to meet with Dr. Ian Pavord (University of Oxford, Oxford, UK) and Dr. Simon Couillard (University of Oxford, Oxford, UK and University of Sherbrooke, Sherbrooke, Canada) to learn about the OxfoRd Asthma attaCk risk ScaLE (ORACLE), a proof-of-concept scale to predict asthma attacks. You can view the prototype Oxford Asthma Attack Risk ScaLE (ORACLE)Â here.
The abstract ‘A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE).‘ was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
1. Could you give us an overview of how the ORACLE scale works? (0:31)
2. Could you give us an overview of your proof-of concept study and its findings? (4:44)
3. What were the limitations of this study and what will be the next steps in the validation of this scale? (8:21)
Disclosures: In the last 5 years Ian Pavord has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 he was an expert witness for a patent dispute involving Astra Zeneca and Teva. Simon Couillard has received a non-restricted research grant from Sanofi Genzyme for investigator-initiated type-2 innovation research; speaker honoraria from Sanofi-Regeneron and AstraZeneca; all outside the submitted work.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ATSÂ 2021 (Virtual).
